WO2016199430A1 - セラノスティクス用のバブル製剤(tb)及びその使用方法 - Google Patents
セラノスティクス用のバブル製剤(tb)及びその使用方法 Download PDFInfo
- Publication number
- WO2016199430A1 WO2016199430A1 PCT/JP2016/002810 JP2016002810W WO2016199430A1 WO 2016199430 A1 WO2016199430 A1 WO 2016199430A1 JP 2016002810 W JP2016002810 W JP 2016002810W WO 2016199430 A1 WO2016199430 A1 WO 2016199430A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bubble
- dspe
- peg
- theranostics
- bubble preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 title claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 49
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims abstract description 33
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims abstract description 31
- 238000000576 coating method Methods 0.000 claims abstract description 26
- 239000011248 coating agent Substances 0.000 claims abstract description 25
- -1 anionic lipid Chemical class 0.000 claims abstract description 23
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960004065 perflutren Drugs 0.000 claims abstract description 22
- 238000002604 ultrasonography Methods 0.000 claims abstract description 22
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 20
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 229950003332 perflubutane Drugs 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 239000000725 suspension Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 14
- 238000003745 diagnosis Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 229960003082 galactose Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 229940041290 mannose Drugs 0.000 claims description 2
- 229960004692 perflenapent Drugs 0.000 claims description 2
- 229960004624 perflexane Drugs 0.000 claims description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 claims description 2
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 29
- 239000007789 gas Substances 0.000 description 27
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 238000003384 imaging method Methods 0.000 description 13
- 108060001084 Luciferase Proteins 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002101 nanobubble Substances 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- WKJDWDLHIOUPPL-JSOSNVBQSA-N (2s)-2-amino-3-({[(2r)-2,3-bis(tetradecanoyloxy)propoxy](hydroxy)phosphoryl}oxy)propanoic acid Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCC WKJDWDLHIOUPPL-JSOSNVBQSA-N 0.000 description 4
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 4
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 4
- IJFVSSZAOYLHEE-SSEXGKCCSA-N 1,2-dilauroyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-N 0.000 description 4
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 description 4
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 4
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 4
- 239000002961 echo contrast media Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 3
- ZLGYVWRJIZPQMM-HHHXNRCGSA-N 2-azaniumylethyl [(2r)-2,3-di(dodecanoyloxy)propyl] phosphate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCC ZLGYVWRJIZPQMM-HHHXNRCGSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 description 3
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 3
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000012285 ultrasound imaging Methods 0.000 description 3
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- IBUKXRINTKQBRQ-KCKFLZCVSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-D-myo-inositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O IBUKXRINTKQBRQ-KCKFLZCVSA-N 0.000 description 2
- RHODCGQMKYNKED-SXOMAYOGSA-N 1,2-dilauroyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCC RHODCGQMKYNKED-SXOMAYOGSA-N 0.000 description 2
- YFWHNAWEOZTIPI-DIPNUNPCSA-N 1,2-dioctadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCCCC YFWHNAWEOZTIPI-DIPNUNPCSA-N 0.000 description 2
- OZSITQMWYBNPMW-GDLZYMKVSA-N 1,2-ditetradecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCC OZSITQMWYBNPMW-GDLZYMKVSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- FQZQXPXKJFOAGE-KICCZPNWSA-N [(2r)-3-[hydroxy-[(5r)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(O)[C@@H](O)C1O FQZQXPXKJFOAGE-KICCZPNWSA-N 0.000 description 2
- LYBDVVBIMGTZMB-HVIJGSDCSA-N [3-[hydroxy-[(2s,3r,5s,6s)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxy-2-tetradecanoyloxypropyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COP(O)(=O)OC1[C@@H](O)[C@@H](O)C(O)[C@@H](O)[C@@H]1O LYBDVVBIMGTZMB-HVIJGSDCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 239000000924 antiasthmatic agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229930183167 cerebroside Natural products 0.000 description 2
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- COQIQRBKEGPRSG-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoro-2-(trifluoromethyl)propane Chemical compound FC(F)(F)C(F)(C(F)(F)F)C(F)(F)F COQIQRBKEGPRSG-UHFFFAOYSA-N 0.000 description 1
- GTTNGNCJHFPTQV-UHFFFAOYSA-N 1,1,1,2,3,3,5,5,5-nonafluoro-2,4,4-tris(trifluoromethyl)pentane Chemical compound FC(F)(F)C(F)(C(F)(F)F)C(F)(F)C(C(F)(F)F)(C(F)(F)F)C(F)(F)F GTTNGNCJHFPTQV-UHFFFAOYSA-N 0.000 description 1
- FVXDQWZBHIXIEJ-LNDKUQBDSA-N 1,2-di-[(9Z,12Z)-octadecadienoyl]-sn-glycero-3-phosphocholine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC FVXDQWZBHIXIEJ-LNDKUQBDSA-N 0.000 description 1
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ZTNFQEXYTMNFHG-SOFXVBFTSA-N PS(18:2(9Z,12Z)/18:2(9Z,12Z)) Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC ZTNFQEXYTMNFHG-SOFXVBFTSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000012607 Thrombomodulin Human genes 0.000 description 1
- 108010079274 Thrombomodulin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- SSCDRSKJTAQNNB-WVZYQCMWSA-N [3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC SSCDRSKJTAQNNB-WVZYQCMWSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- AKWGRDPPGYFWIW-MAZCIEHSSA-N dilinoleoyl phosphatidylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC AKWGRDPPGYFWIW-MAZCIEHSSA-N 0.000 description 1
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229940053382 meglumine antimonate Drugs 0.000 description 1
- XOGYVDXPYVPAAQ-SESJOKTNSA-M meglumine antimoniate Chemical compound O[Sb](=O)=O.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO XOGYVDXPYVPAAQ-SESJOKTNSA-M 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a bubble preparation (TB) for theranostics that enables diagnosis and treatment of a target tissue, and a method of using the bubble preparation for theranostics.
- TB bubble preparation
- Ultrasound contrast agent is a suspension of microbubbles
- ultrasound contrast agents used in Japan mainly include Levovist (registered trademark) and Sonazoid (registered trademark).
- Levovist is used as a diagnosis of cardiovascular angiography
- sonazoid is used for diagnosis of liver cancer and mammary tumor by Kupffer cell imaging.
- the film of Levovist is composed of galactose, which is a carbohydrate, and air is enclosed inside.
- the sonazoid coating is composed of phosphatidylserine sodium, which is a phospholipid, and perflubutane is enclosed inside.
- ultrasound has the advantage that non-invasive, simple, relatively low cost, and real-time diagnostic imaging can be obtained. Therefore, the ultrasonic diagnostic apparatus has become an indispensable diagnostic method in a wide range of clinical fields.
- the physical energy of ultrasound has already been applied not only to diagnosis but also to treatment in clinical settings.
- Non-Patent Documents 1 and 2 a method of delivering a drug or gene into cells by using a combination of microbubbles, which are ultrasonic contrast agents clinically applied for the purpose of angiography, and ultrasonic irradiation has been reported (Non-Patent Documents 1 and 2). ).
- This method can be introduced efficiently only to the site irradiated with ultrasonic waves by temporally and spatially controlling the collapse (cavitation) of microbubbles caused by ultrasonic irradiation from outside the body.
- in-vitro and in-vivo gene introduction in various tissues has been reported.
- HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) treatment which is becoming popular for destroying cancer cells without putting a scalpel into the body, is a high-intensity ultrasound (eg, 3000-5000 W / cm 2 energy intensity) ) Is collected from outside the body to one point of cancer tissue in the body, and the cancer tissue is cauterized and necrotized by thermal energy (thermal action) and cavitation (non-thermal action) (Patent Document 1). This effect is due to the destruction of cancer cells by cauterization of the cancer cells by heat energy that reaches about 80-90 ° C. at the focal point.
- HIFU HIGH INTENSITY FOCUSED ULTRASOUND
- the range that can be irradiated and cauterized at one time is, for example, 3 mm ⁇ 3 mm ⁇ 10 mm, so it is necessary to repeatedly irradiate while shifting the focus.
- the focus shift is extremely dangerous, so it is performed under the guidance of MRI and ultrasound images.
- the skin and surrounding parts become hot, it is necessary to ensure precise control and cooling time constantly. Therefore, usually 2 to 4 hours of treatment time is required.
- HIFU is ideal for non-invasive treatment, but if a bubble preparation having a therapeutic function can be present in cancer tissue, for example, 1/100 to higher than the high-intensity ultrasound used in HIFU. Cancer treatment by cavitation may be possible only at a site where bubbles exist with low-intensity ultrasound as weak as about 1/500.
- the present invention has been made in view of such a problem, and is capable of diagnosing and treating a target tissue by low-intensity ultrasonic irradiation, and a bubble formulation for theranostics and a bubble formulation for the theranostics.
- the purpose is to provide a method of use.
- the bubble formulation (TB) for thelanostics comprises a lipid coating and a gas enclosed in the lumen of the coating, and diagnoses the target tissue by applying ultrasonic waves for low intensity treatment.
- a bubble formulation for theranostics that enables (Diagnostics) and Therapeutics, wherein the coating comprises distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), and 1,2-distearoyl- Sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol)] (DSPE-PEG) is an anionic lipid formed by coating at a molar ratio of 22-60: 30-68: 4-12 And the gas contains at least one of perfluoropropane, perfluorobutane, perfluoropentane, and perfluorohexane, or a mixed gas. It is characterized by doing.
- the method of using the bubble formulation for thelanostics (TB) according to the present invention comprises introducing a suspension in which the bubble formulation for theranostics according to the present invention is suspended in water for injection into the target tissue, Diagnosis by contrast imaging of the target tissue by applying diagnostic ultrasound consisting of frequency to the target tissue, and cavitation phenomenon by applying low-intensity therapeutic ultrasound consisting of the second frequency to the target tissue The target tissue is treated (Therapeutics).
- the bubble preparation for theranostics according to the present invention can resonate and resonate for a long time without being broken by irradiation of diagnostic ultrasonic waves. It is. Further, according to the present invention, diagnosis and treatment of a target tissue by low-intensity therapeutic ultrasonic irradiation can be performed. Using low-intensity focused ultrasound (Low-Intensity-Focused-Ultrasound, LOFU), the temperature at the focal point does not rise and the safety is high. As a result, it is expected to construct an ultrasonic theranostics system for early diagnosis and treatment of highly safe thrombus and minimally invasive treatment of brain function disease and kidney disease.
- LOFU low-intensity focused ultrasound
- FIG. 3 is a diagram showing ultrasonic imaging images in the case of time lapse in a sonazoid (comparative example), a perfluoropropane gas-encapsulated bubble preparation, and a perfluorobutane gas-enclosed bubble preparation.
- FIG. 3 is a diagram showing an ultrasound imaging image when a tumor site is enlarged in a sonazoid (comparative example) and a perfluoropropane gas-encapsulated bubble preparation.
- the bubble formulation for theranostics comprises a film made of lipid and a gas enclosed in the lumen of the film.
- the coatings were distearoylphosphatidylcholine (DSPC), distearoylphosphatidylglycerol (DSPG), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol)] (DSPE-PEG ) Is an anionic lipid formed in a molar ratio of 22-60: 30-68: 4-12.
- DSPC distearoylphosphatidylcholine
- DSPG distearoylphosphatidylglycerol
- DSPE-PEG 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N- [methoxy (polyethylene glycol)] Is an anionic lipid formed in a molar ratio of 22-60: 30-68: 4-12.
- the gas is a perfluoro hydrocarbon gas, and specifically contains at least one of perfluoropropane, perfluoroisobutane and perfluoronormal butane, or a mixed gas thereof.
- a particularly preferred perfluorohydrocarbon gas is perfluoropropane because it can be purchased for medical use in Japan.
- perfluoro hydrocarbons other than these can also be included, and specifically, for example, perfluoromethane, perfluoroethane, perfluoroisooctane, perfluoronormal octane, and sulfur hexafluoride.
- the pressure of the gas to be filled is, for example, about 0.1 to 1.0 MPa.
- the bubble preparation for thelanostics according to the present invention is a microbubble in which a hydrophobic fluorocarbon gas is encapsulated with phospholipid and PEG-lipid, and is present in the liquid as a foam having a diameter of 500 nm to 5 ⁇ m.
- the diameter of the bubble preparation for theranostics is measured, for example, by a dynamic light scattering method.
- the coating is formed of DSPC, DSPG and DSPE-PEG at a molar ratio of 22-60: 30-68: 4-12, which increases the retention of perfluorohydrocarbons and allows for the irradiation of diagnostic ultrasound. It shows continuous resonance and resonance without collapsing, which enables continuous ultrasound imaging for a long time.
- phospholipids can be used in addition to DSPE.
- DSPC DSPG and DSPE-PEG constituting the film
- stearyl PEG, palmitoyl PEG, PEG oleate, myristyl PEG, lauroyl PEG and the like can be mentioned in addition to DSPE-PEG.
- the molecular weight of PEG is 500-12000.
- DSPE-PEG is preferably DSPE-PEG 2000 , DSPE-PEG 3000 or DSPE-PEG 5000 , particularly preferably DSPE-PEG 2000 .
- phosphatidylcholines such as dimyristoyl phosphatidylcholine (DMPC), dilauroyl phosphatidylcholine (DLPC), dipalmitoyl phosphatidylcholine (DPPC), dioleoylphosphatidylcholine (DOPC), dilinoleoylphosphatidylcholine; Phosphatidylglycerols such as glycerol (DMPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylglycerol (DOPG), dilinoleoylphosphatidylglycerol; dilauroylphosphatidylethanolamine (DLPE), dimyristoylphosphatidylethanolamine (DMPE), Dipalmitoy
- glyceroglycolipids and sphingoglycolipids can be included in the coating.
- the glyceroglycolipid include sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride, glycosyl diglyceride and the like.
- the glycosphingolipid include galactosyl cerebroside, lactosyl cerebroside, ganglioside and the like.
- the lipid surface of the coating is modified with ligands for target cells, target tissues, and target lesions.
- the ligand include Arginine-Glycine-Aspartic acid (RGD) sequence peptide, Sigma Protein, etc. as a ligand for thrombus, and transferrin, folic acid, hyaluronic acid, galactose or mannose as a ligand for cancer cells.
- Monoclonal antibodies and polyclonal antibodies can also be used as ligands.
- the RGD peptide is preferably used, and the RGD peptide has a function of specifically binding to a cell adhesion factor present on a specific cell or thrombus. Therefore, it is possible to further facilitate visualization of the thrombus by modifying the RGD peptide on the lipid surface of the coating.
- the coating is preferably DSPC, DSPG and DSPE-PEG derivatives.
- DSPE-PEG-Maleimide (MAL), DSPE-PEG-Carboxylic Acid (COOH), DSPE-PEG-N-Hydroxysuccinimide (NHS) or DSPE-PEG-NH 2 is preferable.
- a film stabilizer sitosterol, cholesterol, dihydrocholesterol, cholesterol ester, phytosterol, stigmasterol, campesterol, cholestanol, lanosterol, 1-O— Sterol glucoside, 1-O-sterol maltoside, and mixtures thereof can be included.
- the drug is preferably a drug whose blood concentration is desired to be maintained for a long period of time or a drug that needs to be administered for targeting to a specific disease site or cell.
- the drug is not particularly limited, and examples thereof include anticancer drugs, antibiotics, antiasthma drugs, antithrombotic drugs, antiprotozoal drugs, immunostimulants, peptide drugs, and antiviral drugs.
- the anticancer agent is not particularly limited, and examples thereof include doxorubicin, cisplatin, mitomycin, bleomycin, 5-fluorouracil, methotrexate, nitrogen mustard, busulfan, oxaliplatin, taxol, camptothecin and the like.
- Antibiotics are, for example, sulfazen, gentamicin, streptomycin and the like.
- Anti-asthma drugs are, for example, theophylline.
- Examples of the antithrombotic agent include tPA, heparin, low molecular weight heparin, urokinase, thrombomodulin, streptokinase and the like.
- Antiprotozoal agents are, for example, meglumine antimonate.
- the immunostimulant include muramyl peptides.
- Peptide drugs are, for example, natural or genetically modified ⁇ , ⁇ , ⁇ -interferon, interleukin, superoxide desmutase and the like.
- examples of drugs include arteriosclerosis therapeutic agents such as prostaglandins, NF kappa B for arterial occlusion and Virtua disease, decoy and the like.
- genes are, for example, DNA, RNA, antisense DNA, siRNA, decoy, therapeutic oligonucleotide and the like.
- a bubble formulation for thelanostics according to the present invention is made by contacting a lipid solution with perfluorohydrocarbon gas while stirring so as to form a suspension, and then homogenizer (15000 rpm). , 5 minutes), and emulsifying the organic phase into the aqueous phase.
- the bubble preparation for theranostics according to the present invention can be prepared not only by a homogenizer but also by, for example, shaking.
- a homogenizer for example, a homogenizer
- shaking for example, it is also possible to prepare a nanobubble suspension by putting a liposome solution in a predetermined ratio into a vial and shaking with a vial shaker.
- the freeze-dried powder according to this embodiment is a freeze-dried powder obtained by freeze-drying a suspension in which the bubble formulation for thelanostics according to the present invention is suspended in a sugar solution that is trehalose or sucrose. Is the body.
- freeze-dried additives can be contained for freeze protection and / or dispersion protection.
- Lyophilized additives include, for example, amino acids such as glycine; saccharides such as mannitol, maltose, glucose, lactose, inulin, sucrose, trehalose or cyclodextrin; polysaccharides such as dextran and chitosan; or polyethylene glycol Examples include polyoxyalkylene glycol.
- This freeze-dried powder can be stored for a long period of 3 months or longer, and can be restored and used with water for injection and perfluorohydrocarbon gas such as perfluoropropane described above.
- the bubble formulation for thelanostics according to the present invention is used as follows. That is, a suspension in which the bubble formulation for thelanostics according to the present invention is suspended in water for injection is introduced into the target tissue.
- the target tissue is not particularly limited, but is, for example, a cancer tissue.
- diagnosis by contrast imaging of the target tissue is performed by applying diagnostic ultrasonic waves having the first frequency to the target tissue.
- the first frequency is, for example, 3 MHz to 20 MHz.
- a microstreaming phenomenon occurs by applying the first frequency.
- the nanobubbles repeatedly expand and contract by the sound pressure intensity of the ultrasonic waves and vibrate locally.
- the target tissue is treated by the cavitation phenomenon by applying low-intensity ultrasonic waves having the second frequency to the target tissue.
- the second frequency is, for example, 0.5 MHz to 3.0 MHz.
- Cavitation is a phenomenon in which jet pressure is generated by releasing a large pressure when nanobubbles collapse.
- Example 1 ⁇ Preparation of bubble preparation for theranostics> DSPC, DSPG and DSPE-PEG 2000 -OMe in contact with a perfluoropropane gas (gas flow rate 12 ml / min) with stirring in an anionic lipid solution of 22:68:10 molar ratio to form a suspension I let you. Then, the bubble suspension was produced by emulsifying the gas using a homogenizer (15000 rpm, 5 minutes).
- a bubble suspension was prepared in the same manner as above except that the molar ratio of DSPC, DSPG and DSPE-PEG 2000 -OMe in the anionic lipid solution was changed as follows.
- a bubble suspension was prepared in the same manner as above except that the molar ratio of DSPC, DSPG and DSPE-PEG 2000 -OMe in the anionic lipid solution was changed as follows.
- FIG. 2 is a diagram showing the persistence of nanobubbles when the coating component ratio is variously changed.
- the bubble needs to be retained and stable in the blood vessel and in the tumor.
- the bubble preparation according to the present invention is more time consuming than the bubble preparation according to the comparative example.
- the retention was very good.
- Example 2 ⁇ Continuous imaging in cancer-bearing mice> Next, the possibility of continuous oscillation was observed with diagnostic ultrasound in cancer-bearing mice, and blood flow imaging was taken.
- Nanobubbles are brought into contact with perfluoropropane gas while stirring an anionic lipid solution formed of DSPC, DSPG and DSPE-PEG 2000 -OMe in a molar ratio of 22:68:10 to form a suspension. Thereafter, the organic phase was emulsified into an aqueous phase using a homogenizer (15000 rpm, 5 minutes). Next, a bubble preparation was prepared in the same manner as described above except that perfluorobutane gas was used.
- Ultrasonic imaging was performed using a diagnostic ultrasonic device to determine whether the nanobubbles reached the tumor site.
- LOGIQ E9 from GE Healthcare was used as the diagnostic ultrasonic device.
- FIG. 3 is a diagram showing ultrasonic imaging images in the case of time lapse in the sonazoid (comparative example), the perfluoropropane gas-encapsulated bubble preparation, and the perfluorobutane gas-enclosed bubble preparation.
- a stronger echo signal was observed from the tumor site than in the comparative example, and stable reachability of the present bubble preparation could be confirmed.
- a strong echo signal could be observed over time.
- FIG. 4 is a view showing an ultrasound imaging image when a tumor site is enlarged in a sonazoid (comparative example) and a perfluoropropane gas-encapsulated bubble preparation. As shown in FIG. 4, in this example, a stronger echo signal was observed from the tumor site than in the comparative example.
- Example 3 ⁇ Ultrasound gene introduction> Next, we evaluated the function of the gene transfer system using perfluoropropane gas-filled bubble preparation (TB) and low-intensity ultrasonic irradiation.
- TB perfluoropropane gas-filled bubble preparation
- a perfluoropropane gas-encapsulated bubble preparation (50 nmol) according to the present example and a pDNA encoding a reporter gene (Luciferase) were administered to a mouse via the tail vein (100 ⁇ g), and immediately a part of the liver was transcutaneously.
- US therapeutic ultrasonic irradiation
- FIG. 5 is a graph showing an increase in luciferase activity.
- luciferin substrate 15 mg / mL, 200 ⁇ L
- FIG. 6 shows the results of in vivo luminescence imaging. As shown in FIGS. 5 and 6, the expression of luciferase was observed only from the liver irradiated with therapeutic ultrasonic waves.
- the perfluoropropane gas-encapsulated bubble preparation (5 nmol / sample) according to this example and pDNA (5 ⁇ g / sample) encoding the reporter gene (Luciferase) were added to the Colon26 cultured cell solution for treatment.
- pDNA 5 ⁇ g / sample
- reporter gene Lucinerase
- the perfluoropropane gas-encapsulated bubble preparation (TB) and the delivery system using ultrasonic irradiation for low-intensity treatment according to this example proved to be useful in cancer gene / nucleic acid therapy. did.
- Example 4 ⁇ Creation of bubble preparation by shaking>
- a bubble suspension was prepared by emulsifying gas using a homogenizer.
- Example 4 shows the production of a bubble suspension by shaking.
- Example 5 ⁇ Evaluation of binding ability of peptide-modified bubble prepared by homogenizer to target cells> DSPE-PEG 3400 modified with cyclic RGD (cRGD) was prepared as a peptide-modified lipid.
- cRGD cyclic RGD
- CRGD is a peptide sequence that specifically binds to ⁇ V ⁇ 3 integrin that is overexpressed on the surface of neovascular endothelial cells of cancer tissue. Targeting bubbles that bind to can be prepared.
- HUVEC Human umbilical vein endothelial cells
- cyclic RAD (cRAD) was used as a control peptide that does not bind to HUVEC.
- the cRAD-modified bubble was prepared in the same manner as the cRGD-modified bubble and was modified to 5 mol%.
- CRGD or cRAD modified bubble (DiI label) was added to HUVEC cells and incubated at 37 ° C. for 10 minutes. Thereafter, the cells were washed, and the binding of bubbles to cells was evaluated with a flow cytometer. As shown in FIG. 9, the cRGDRG5 mol% modified bubble prepared by the homogenizer showed excellent binding to HUVEC cells compared to the cRAD 5 mol% modified bubble.
- Example 6 ⁇ Evaluation of binding ability of peptide-modified bubble prepared by shaking to target cells>
- Example 5 the binding property of peptide modified bubbles prepared using a homogenizer to HUVEC cells was shown.
- Example 6 shows the binding property of peptide-modified bubbles prepared by shaking to HUVEC cells.
- DSPE-PEG 3400 modified with cyclic RGD was prepared as a peptide-modified lipid.
- DSPC: DSPG: DSPE-PEG 2000 -OMe: cRGD modified DSPE-PEG 3400 1 mL of 30: 60: 5: 5 or 30: 60: 0: 10 (molar ratio) liposome (lipid concentration: 0.5 mM) in a vial
- the head space in the vial was replaced with perfluoropropane gas and cooled on ice. Thereafter, the mixture was shaken for 45 seconds with a vial shaker and cooled on ice again.
- cRGD-modified bubbles In order to remove large bubbles, the vial was allowed to stand upside down for about 15 minutes, and the lower part of the bubble suspension was recovered to prepare cRGD-modified bubbles.
- cRGD modification a modified bubble of 5 mol% modification and a modified bubble of 10 mol% modification were prepared.
- cyclic RAD (cRAD) was used as a control peptide.
- the cRAD-modified bubble was prepared by shaking in the same manner as the cRGD-modified bubble, and a 5 mol% modified bubble and a 10 mol% modified bubble were prepared.
- cRGD or cRAD modified bubble (DiO label) was added to HUVEC cells and incubated at 37 ° C. for 30 minutes. Thereafter, the cells were washed, and the binding of bubbles to cells was evaluated with a flow cytometer.
- the cRGD 5 mol% modified bubble prepared by shaking showed superior binding to HUVEC cells compared to the cRAD 5 mol% modified bubble.
- the cRGD 10 mol% modified bubble prepared by shaking also showed excellent binding to HUVEC cells compared to the cRAD 10 mol% modified bubble.
- mouse melanoma cells (B16BL6 cells) 1 ⁇ 10 6 cells / 50 ⁇ L / mouse were transplanted subcutaneously in the back of the C57BL / 6j mouse, 7 days after tumor bearing, 25 ⁇ L of bubble through a 5 ⁇ m filter was administered intratumorally, Immediately thereafter, ultrasonic waves were irradiated percutaneously toward the tumor.
- the ultrasonic irradiation conditions were as follows. Device: sonitron2000 (Neppagene Corporation) Freqency: 1MHz Intensity: 4W / cm 2 Duty: 50% Time: 120sec Burst Rate: 2Hz
- the tumor volume was calculated by the following formula: (tumor major axis ⁇ tumor minor axis ⁇ tumor minor axis) ⁇ 0.5 (mm 3 ), and the antitumor effect was evaluated using the tumor diameter as an index. As shown in FIG. 12, the excellent antitumor effect of the bubble according to this example was found.
Abstract
Description
本実施形態にかかるセラノスティクス用のバブル製剤は、脂質からなる被膜と、この被膜の内腔に封入されたガスとからなる。
本発明にかかるセラノスティクス用のバブル製剤は、図1に示されるように、脂質溶液を、懸濁液を生成するように撹拌しながらパーフルオロ炭化水素ガスに接触させ、その後、ホモジナイザー(15000 rpm, 5分)を用いて有機相を水性相に乳化することにより、ナノバブル懸濁液として製造可能である。
本実施形態にかかる凍結乾燥粉末体は、本発明にかかるセラノスティクス用のバブル製剤が、トレハロース又はスクロースである糖質の溶液に懸濁している懸濁液を凍結乾燥させて得られる凍結乾燥粉末体である。
本発明にかかるセラノスティクス用のバブル製剤は、下記のように使用する。即ち、本発明にかかるセラノスティクス用のバブル製剤が注射用水に懸濁されている懸濁液を対象組織に導入する。対象組織は特に限定されるものではないが、例えば癌組織である。
第1の周波数による診断用超音波を対象組織に作用させることにより対象組織の造影が可能となり、造影できるということはその部位に向かって第2の周波数による低強度超音波又はLOFUを照射すればキャビテーションによる治療が可能となる。更に、低強度超音波又はLOFUのみの照射では焦点部位の温度は上がらないので、安全性の高い低侵襲的な治療が可能となる。
DSPC、DSPG及びDSPE-PEG2000-OMeを22:68:10のモル比のアニオニック脂質溶液を、懸濁液を生成するように撹拌しながらパーフルオロプロパンガス(ガス流量は12ml/分)に接触させた。その後、ホモジナイザー(15000 rpm, 5分)を用いてガスを乳化することにより、バブル懸濁液を作製した。
DSPC:DSPG:DSPE-PEG2000-OMe=36:54:10
DSPC:DSPG:DSPE-PEG2000-OMe=45:45:10
DSPC:DSPG:DSPE-PEG2000-OMe=54:36:10
DSPC:DSPG:DSPE-PEG2000-OMe=60:30:10
また比較例としてアニオニック脂質溶液におけるDSPC、DSPG及びDSPE-PEG2000-OMeのモル比を下記のように変更した以外は、上記と同じようにバブル懸濁液を作製した。
DSPC:DSPG:DSPE-PEG2000-OMe=90:0:10
このようにして被膜成分割合を種々変更させて複数のバブル製剤を作製した。図2は、被膜成分割合を種々変更した場合におけるナノバブルの持続性を示す図である。バブルには血管内及び腫瘍内での滞留性及び安定性が必要であるが、図2に示されるように、比較例にかかるバブル製剤と比べて、本発明にかかるバブル製剤は時間が経過しても滞留性が極めて良好であった。
次に、担がんマウスでの診断用超音波で持続的なオシレーションの可能性を観察し、血流イメージングを撮影した。
次にパーフルオロプロパンガス封入バブル製剤(TB)と低強度超音波照射併用による遺伝子導入システムの機能評価を行った。In vivo 実験では、本実施例にかかるパーフルオロプロパンガス封入バブル製剤(50nmol)と、レポーター遺伝子(Luciferase)をコードしたpDNAとともにマウスに尾静脈投与し(100μg)、ただちに経皮的に肝臓の部分をソニトロン プローブ(12nm)を使用して治療用超音波照射(US)(1MHz, 50% duty, 1W/cm2, 60sec.)した。図5はルシフェラーゼ活性の上昇を示す図である。in vivo発光イメージングでは、イソフルラン麻酔下のマウスに対してルシフェリン基質(15 mg/mL, 200μL)を投与後、IVISイメージングシステムを用いて、発光を検出、定量化した。図6はin vivo発光イメージングの結果を示す図である。図5及び図6に示されるように、治療用超音波を照射した肝臓からのみルシフェラーゼの発現が観察された。
実施例1ではホモジナイザーを用いてガスを乳化することにより、バブル懸濁液を作製した。実施例4ではシェイキングによるバブル懸濁液の作製を示す。
ペプチド修飾脂質としてcyclic RGD(cRGD)で修飾したDSPE-PEG3400を用意した。なお、cRGDはがん組織の新生血管内皮細胞の表面上に過剰発現しているαVβ3インテグリンに特異的に結合するペプチド配列であり、バブル表面に修飾することで、標的細胞に選択的に結合するターゲティング型バブルを調製できる。そしてDSPC:DSPG:DSPE-PEG2000-OMe: cRGD修飾DSPE-PEG3400=30:60:5:5(モル比)のアニオニック脂質溶液を、懸濁液を生成するように撹拌しながらパーフルオロプロパンガス(ガス流量は12ml/分)に接触させた。その後、ホモジナイザー(15000 rpm, 5分)を用いてガスを乳化することによりバブル懸濁液を作製してcRGD修飾バブルを用意した。cRGD修飾は5モル%修飾とした。
実施例5ではホモジナイザーを用いて作製したペプチド修飾バブルのHUVEC細胞への結合性を示した。実施例6ではシェイキングで作製したペプチド修飾バブルのHUVEC細胞への結合性を示す。
DSPC:DSPG:DSPE-PEG2000-OMe=30:60:10(モル比)のアニオニック脂質溶液を、懸濁液を生成するように撹拌しながらパーフルオロプロパンガス(ガス流量は12ml/分)に接触させた。その後、ホモジナイザー(15000 rpm, 5分)を用いてガスを乳化することによりバブル懸濁液を作製した。そしてこのバブル懸濁液を凍結乾燥させて凍結乾燥粉末体を得た。この凍結乾燥粉末体に2mLの超純水(2mL MilliQ)を添加して懸濁させた。
装置:sonitron2000(ネッパジーン株式会社)
Freqency:1MHz
Intensity:4W/cm2
Duty:50%
Time:120sec
Burst Rate:2Hz
腫瘍体積は、(腫瘍の長径×腫瘍の短径×腫瘍の短径)×0.5(mm3)なる計算式により算出し、腫瘍径を指標に抗腫瘍効果を評価した。図12に示されるように本実施例にかかるバブルの優れた抗腫瘍効果が判明した。
Claims (10)
- 脂質からなる被膜と、前記被膜の内腔に封入されたガスとからなり、診断用超音波と低強度治療用超音波を作用させることにより、対象組織の診断(Diagnostics)及び治療(Therapeutics)を可能とするセラノスティクス用のバブル製剤であって、
前記被膜は、ジステアロイルホスファチジルコリン(DSPC)、ジステアロイルホスファチジルグリセロール(DSPG)、及び、1,2-ジステアロイル-sn-グリセロ-3-ホスホエタノールアミン-N-[メトオキシ(ポリエチレングリコール)](DSPE-PEG)を、22~60:30~68:4~12のモル比にて形成されたアニオニック脂質であり、
前記ガスは、パーフルオロプロパン、パーフルオロブタン、パーフルオロペンタン、及び、パーフルオロヘキサンの少なくとも何れか又は混合ガスを含有することを特徴とするセラノスティクス用のバブル製剤。 - 前記被膜は、ジステアロイルホスファチジルコリン(DSPC)とジステアロイルホスファチジルグリセロール(DSPG)、及び、1,2-ジステアロイル-sn-グリセロ-3-ホスホエタノールアミン-N-[メトオキシ(ポリエチレングリコール)](DSPE-PEG)を、30:60:10の重量比にて形成されたアニオニック脂質であり、
前記ガスはパーフルオロプロパンであることを特徴とする請求項1に記載のセラノスティクス用のバブル製剤。 - 前記低強度治療用超音波は0.03~50W/cm2のエネルギー強度であることを特徴とする請求項1又は2に記載のセラノスティクス用のバブル製剤。
- 直径が500nm~5μmである請求項1乃至3の何れか1項に記載のセラノスティクス用のバブル製剤。
- 前記被膜は、DSPC、DSPG及びDSPE-PEG誘導体であり、
前記DSPE-PEG誘導体は、DSPE-PEG-MAL、DSPE-PEG-COOH、DSPE-PEG-NHS又はDSPE-PEG-NH2であることを特徴とする請求項1乃至4の何れか1項に記載のセラノスティクス用のバブル製剤。 - 前記被膜の脂質表面にリガンドが修飾されており、
前記リガンドは、Arginine-Glycine-Aspartic acid(RGD)配列ペプチド、トランスフェリン、葉酸、ヒアルロン酸、ガラクトース又はマンノースであることを特徴とする請求項5に記載のセラノスティクス用のバブル製剤。 - 請求項1乃至6の何れか1項に記載のセラノスティクス用のバブル製剤が、トレハロース、イヌリン又はスクロースである糖質の溶液に懸濁している懸濁液を凍結乾燥させて得られる凍結乾燥粉末体。
- 請求項1乃至6の何れか1項に記載のセラノスティクス用のバブル製剤が注射用水に懸濁されている懸濁液を対象組織に導入し、
第1の周波数からなる造影用超音波を対象組織に作用させることにより対象組織の造影による診断(Diagnostics)を行い、
第2の周波数からなる低強度超音波又は低強度収束超音波を対象組織に作用させることによりキャビテーション現象による対象組織の治療(Therapeutics)を行うことを特徴とするセラノスティクス用のバブル製剤の使用方法。 - 前記第1の周波数は3.0MHz~20MHzであり、前記第2の周波数は0.5MHz~3.0MHzであることを特徴とする請求項8に記載のセラノスティクス用のバブル製剤の使用方法。
- 前記対象組織は癌組織であることを特徴とする請求項8又は9に記載のセラノスティクス用のバブル製剤の使用方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017523117A JP6804095B2 (ja) | 2015-06-10 | 2016-06-10 | セラノスティクス用のバブル製剤(tb)及びその使用方法 |
CN201680033821.2A CN107708742B (zh) | 2015-06-10 | 2016-06-10 | 诊断治疗用气泡制剂(tb)及其使用方法 |
EP16807137.1A EP3308779B1 (en) | 2015-06-10 | 2016-06-10 | Theranostic bubble preparation (tb), and method for using same |
US15/579,140 US10688199B2 (en) | 2015-06-10 | 2016-06-10 | Theranostic bubble preparation (TB), and method for using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015117793 | 2015-06-10 | ||
JP2015-117793 | 2015-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016199430A1 true WO2016199430A1 (ja) | 2016-12-15 |
Family
ID=57503218
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/002810 WO2016199430A1 (ja) | 2015-06-10 | 2016-06-10 | セラノスティクス用のバブル製剤(tb)及びその使用方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10688199B2 (ja) |
EP (1) | EP3308779B1 (ja) |
JP (1) | JP6804095B2 (ja) |
CN (1) | CN107708742B (ja) |
WO (1) | WO2016199430A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514941A (ja) * | 2018-02-05 | 2021-06-17 | ビリックス カンパニー リミテッドBilix Co.,Ltd. | ビリルビン誘導体基盤の診断および治療用超音波造影剤 |
JP7361297B2 (ja) | 2019-08-27 | 2023-10-16 | 株式会社エーワンテクニカ | バブル製剤の製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3897954B1 (en) * | 2018-12-21 | 2024-05-01 | Bracco Suisse SA | Gas-filled microvesicles with ligand |
CN113041365B (zh) * | 2021-03-25 | 2022-04-08 | 黑龙江中医药大学 | 一种增强颈动脉硬化超声诊断的靶向超声造影剂及其制备方法 |
CN114767886A (zh) * | 2022-05-16 | 2022-07-22 | 河北医科大学第二医院 | 一种新型适用于乳腺超声造影剂及其应用 |
CN115154472A (zh) * | 2022-07-27 | 2022-10-11 | 北京大学第三医院(北京大学第三临床医学院) | 一种具有靶向功能的治疗脑卒中的氢化可的松多功能超声微泡 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001205061A (ja) * | 2000-01-28 | 2001-07-31 | Nippon Bee Kk | パーフルオロカーボン乳化製剤の製造法 |
JP2003048826A (ja) * | 2001-05-31 | 2003-02-21 | Nof Corp | パーフルオロカーボン乳剤及びその製造方法 |
US20050025710A1 (en) * | 2003-07-29 | 2005-02-03 | Michel Schneider | Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging |
JP2007516957A (ja) * | 2003-06-13 | 2007-06-28 | イマルクス セラピューティクス インコーポレーティッド | 改変超音波技術を使用する非侵襲性血管内血栓溶解 |
JP2009161549A (ja) * | 2002-03-01 | 2009-07-23 | Dyax Corp | Kdrおよびvegf/kdr結合ペプチドならびに診断および治療におけるその使用 |
JP2010512400A (ja) * | 2006-12-11 | 2010-04-22 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | フィブリン結合ペプチドおよびそのコンジュゲート |
JP2011057591A (ja) * | 2009-09-08 | 2011-03-24 | Fujifilm Corp | リポソーム、並びに診断用造影剤、治療促進剤、及び医薬組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0881915B1 (en) * | 1996-02-19 | 2003-04-23 | Amersham Health AS | Improvements in or relating to contrast agents |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
KR101076053B1 (ko) * | 2003-02-04 | 2011-10-21 | 브라코 인터내셔날 비.브이. | 초음파 조영제 및 그것의 제조방법 |
KR101101931B1 (ko) * | 2003-04-25 | 2012-01-03 | 이지파워 코포레이션 | 손상된 볼트 및 나사 제거 장치 |
WO2006094951A1 (en) * | 2005-03-03 | 2006-09-14 | Bracco Research Sa | Medical imaging system based on a targeted contrast agent |
WO2007084508A2 (en) | 2006-01-13 | 2007-07-26 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
CA2649119A1 (en) | 2006-04-13 | 2007-12-13 | Mirabilis Medica, Inc. | Methods and apparatus for the treatment of menometrorrhagia, endometrial pathology, and cervical neoplasia using high intensity focused ultrasound energy |
EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
US10279053B2 (en) * | 2011-07-19 | 2019-05-07 | Nuvox Pharma Llc | Microbubble compositions, method of making same, and method using same |
WO2014030601A1 (ja) * | 2012-08-20 | 2014-02-27 | 国立大学法人京都大学 | アニオン性を有する新規ナノバブルポリ-リポ・プレックスの製造方法 |
TWI552761B (zh) * | 2013-05-03 | 2016-10-11 | 博信生物科技股份有限公司 | 一種脂質微/奈米氣泡、及其最佳化之製備方法及製備裝置 |
-
2016
- 2016-06-10 CN CN201680033821.2A patent/CN107708742B/zh active Active
- 2016-06-10 JP JP2017523117A patent/JP6804095B2/ja active Active
- 2016-06-10 US US15/579,140 patent/US10688199B2/en active Active
- 2016-06-10 WO PCT/JP2016/002810 patent/WO2016199430A1/ja active Application Filing
- 2016-06-10 EP EP16807137.1A patent/EP3308779B1/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001205061A (ja) * | 2000-01-28 | 2001-07-31 | Nippon Bee Kk | パーフルオロカーボン乳化製剤の製造法 |
JP2003048826A (ja) * | 2001-05-31 | 2003-02-21 | Nof Corp | パーフルオロカーボン乳剤及びその製造方法 |
JP2009161549A (ja) * | 2002-03-01 | 2009-07-23 | Dyax Corp | Kdrおよびvegf/kdr結合ペプチドならびに診断および治療におけるその使用 |
JP2007516957A (ja) * | 2003-06-13 | 2007-06-28 | イマルクス セラピューティクス インコーポレーティッド | 改変超音波技術を使用する非侵襲性血管内血栓溶解 |
US20050025710A1 (en) * | 2003-07-29 | 2005-02-03 | Michel Schneider | Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging |
JP2010512400A (ja) * | 2006-12-11 | 2010-04-22 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | フィブリン結合ペプチドおよびそのコンジュゲート |
JP2011057591A (ja) * | 2009-09-08 | 2011-03-24 | Fujifilm Corp | リポソーム、並びに診断用造影剤、治療促進剤、及び医薬組成物 |
Non-Patent Citations (2)
Title |
---|
JAVADI M. ET AL.: "Encapsulating Nanoemulsions Inside eLiposomes for Ultrasonic Drug Delivery.", LANGMUIR, vol. 28, no. 41, 2012, pages 14720 - 14729, XP055333550 * |
SAX N. ET AL.: "Optimization of Acoustic Liposomes for Improved In Vitro and In Vivo Stability.", PHARMACEUTICAL RESEARCH, vol. 30, no. 1, 2013, pages 218 - 224, XP035152043 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514941A (ja) * | 2018-02-05 | 2021-06-17 | ビリックス カンパニー リミテッドBilix Co.,Ltd. | ビリルビン誘導体基盤の診断および治療用超音波造影剤 |
US11571486B2 (en) | 2018-02-05 | 2023-02-07 | Bilix Co., Ltd. | Bilirubin derivative-based diagnostic and therapeutic ultrasound contrast agent |
JP7256554B2 (ja) | 2018-02-05 | 2023-04-12 | ビリックス カンパニー リミテッド | ビリルビン誘導体基盤の診断および治療用超音波造影剤 |
JP7361297B2 (ja) | 2019-08-27 | 2023-10-16 | 株式会社エーワンテクニカ | バブル製剤の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3308779A4 (en) | 2018-05-30 |
EP3308779A1 (en) | 2018-04-18 |
CN107708742B (zh) | 2021-01-15 |
JPWO2016199430A1 (ja) | 2018-04-05 |
EP3308779B1 (en) | 2019-08-07 |
US10688199B2 (en) | 2020-06-23 |
US20180161462A1 (en) | 2018-06-14 |
CN107708742A (zh) | 2018-02-16 |
JP6804095B2 (ja) | 2020-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boissenot et al. | Ultrasound-triggered drug delivery for cancer treatment using drug delivery systems: From theoretical considerations to practical applications | |
JP6804095B2 (ja) | セラノスティクス用のバブル製剤(tb)及びその使用方法 | |
Escoffre et al. | In-vivo gene delivery by sonoporation: recent progress and prospects | |
Zhao et al. | Potential and problems in ultrasound-responsive drug delivery systems | |
Perera et al. | Ultrasound contrast agents and delivery systems in cancer detection and therapy | |
Geis et al. | Microbubbles as a vehicle for gene and drug delivery: current clinical implications and future perspectives | |
Wang et al. | Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implications | |
Sirsi et al. | State-of-the-art materials for ultrasound-triggered drug delivery | |
US10076580B2 (en) | Gas-filled microvesicles composition for contrast imaging | |
US20160279449A1 (en) | Devices and methods for the ultrasound treatment of ischemic stroke | |
Udroiu | Ultrasonic drug delivery in Oncology | |
Chen et al. | New development and application of ultrasound targeted microbubble destruction in gene therapy and drug delivery | |
Alphandéry | Ultrasound and nanomaterial: an efficient pair to fight cancer | |
Wang et al. | Development and application of ultrasound contrast agents in biomedicine | |
Bahutair et al. | Ultrasound triggering of liposomal nanodrugs for cancer therapy: a review | |
Salkho et al. | Liposomes as a promising ultrasound-triggered drug delivery system in cancer treatment | |
Pua et al. | Ultrasound-mediated drug delivery | |
US20070110674A1 (en) | Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems | |
Pichon et al. | Recent advances in gene delivery with ultrasound and microbubbles | |
Choi et al. | Synergistic agents for tumor-specific therapy mediated by focused ultrasound treatment | |
JP2010260828A (ja) | リポソーム、リポソームの製造方法、及び医薬組成物 | |
JP2005154282A (ja) | ガス封入リポソームの製造法 | |
JP2006063052A (ja) | リポソーム含有超音波造影剤およびその製造方法 | |
Thanou et al. | Activatable liposomes: Ultrasound-activated liposomes and lipid vesicles | |
KOOIMAN | ULTRASOUND-RESPONSIVE CAVITATION NUCLEI FOR THERAPY AND DRUG DELIVERY TAGGEDPKLAZINA KOOIMAN,* SILKE ROOVERS, y SIMONE AG LANGEVELD,* ROBERT T. KLEVEN, z HELEEN DEWITTE, y, x,{MEAGHAN A. O’REILLY,║, JEAN-MICHEL ESCOFFRE,** AYACHE BOUAKAZ,** MARTIN D. VERWEIJ,*, y y KULLERVO HYNYNEN,║, INE LENTACKER, y,{ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16807137 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2017523117 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15579140 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016807137 Country of ref document: EP |